KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Expenses (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Operating Expenses for 15 consecutive years, with $215.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 41.08% to $215.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $781.2 million, a 34.66% increase, with the full-year FY2025 number at $781.2 million, up 34.66% from a year prior.
  • Operating Expenses was $215.5 million for Q4 2025 at Supernus Pharmaceuticals, down from $252.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $252.3 million in Q3 2025 to a low of $107.2 million in Q2 2021.
  • A 5-year average of $154.5 million and a median of $151.6 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: fell 18.52% in 2023, then surged 87.13% in 2025.
  • Supernus Pharmaceuticals' Operating Expenses stood at $153.0 million in 2021, then decreased by 13.05% to $133.0 million in 2022, then rose by 24.3% to $165.3 million in 2023, then dropped by 7.6% to $152.8 million in 2024, then soared by 41.08% to $215.5 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Operating Expenses are $215.5 million (Q4 2025), $252.3 million (Q3 2025), and $153.3 million (Q2 2025).